MMR Information Systems, Inc. Shareholder Update Regarding Clinical Trials Data for Cancer Vaccine
March 02, 2010 08:35 ET | MMR Information Systems, Inc.
LOS ANGELES, CA--(Marketwire - March 2, 2010) -  MMR Information Systems (OTCBB: MMRF) (the "Company") disclosed today that it was recently contacted by Ronald Levy, MD, Chief of the Oncology...
One-of-a-Kind Oncology Study by Cutting Edge Information Launches Today, Contains Market Forecasting and Brand Spending Data to 2015
January 28, 2010 09:09 ET | Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwire - January 28, 2010) - Business intelligence firm Cutting Edge Information announces the release of its newest study on the global cancer market, "Oncology...
MMR Information Systems, Inc. to Add Ongoing and Upcoming Clinical Trials to MyMedicalRecords.com Website
November 23, 2009 07:55 ET | MMR Information Systems, Inc.
LOS ANGELES, CA--(Marketwire - November 23, 2009) - MMR Information Systems, Inc. (OTCBB: MMRF) ("MMR") announced today it will add a clinical trials information service to its MyMedicalRecords...
Intralinks Survey: Life Sciences Deal Activity Will Increase in 2010
November 18, 2009 09:00 ET | IntraLinks
NEW YORK, NY--(Marketwire - November 18, 2009) - IntraLinks/BioNetwork West 2009 Facts: -- IntraLinks®, the leading provider of critical information exchange solutions, today announced...
Threshold Pharmaceuticals Announces Clinical Development Results for Cancer Candidate TH-302
November 12, 2009 16:00 ET | Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation related to Threshold's clinical stage hypoxia-activated prodrug,...
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA(TM) in Systemic Lupus Erythematosus
November 02, 2009 00:01 ET | Human Genome Sciences
ROCKVILLE, MD and LONDON--(Marketwire - November 2, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary...
Results From TH-302 Clinical Trials Presented at International Lung Cancer Meeting
August 04, 2009 16:05 ET | Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif and SCOTTSDALE, Ariz, Aug. 4, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) and the Virginia G. Piper Cancer Center at Scottsdale Healthcare today...
Icagen, Inc. Logo
Icagen Announces Lifting of Partial Clinical Hold of ICA-105665
August 03, 2009 06:30 ET | Icagen, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) reported today that the FDA has lifted the partial clinical hold related to the development of ICA-105665, the...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
July 20, 2009 00:01 ET | Human Genome Sciences, Inc.
ROCKVILLE, MD and LONDON--(Marketwire - July 20, 2009) - Human Genome Sciences, Inc. (NASDAQ: HGSI) and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab, formerly...
Penwest Announces Results of Phase Ib Trial of A0001
July 16, 2009 08:00 ET | Penwest Pharmaceuticals Co.
DANBURY, Conn., July 16, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced the results of its Phase Ib clinical trial of A0001, a compound the Company is developing...